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Abstract
We report one case of cardiac arrest related to ciprofloxacin administration. One female patient
(aged 70 years old) developed a marked QTc prolongation (QTc = 0.62 s) within 24 hours of
ciprofloxacin administration, with documented torsades de pointes and recurrent syncope that
required defibrillation. The patient was under amiodarone and sotalol therapy for atrial
fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy. QT prolongation
and subsequent torsades de pointes appeared only after initiation of ciprofloxacin and normal-
ized after drug discontinuation. Even though ciprofloxacin is thought to be safer than other
agents in its class, it may cause QT prolongation and torsades de pointes, particularly in high
risk patients with predisposing factors.
Prolongation of the QT interval related to the effect of fluoroquinolones on rapid potassium
channels (IKr) may result on potentially serious proarrhythmic effect, leading to torsades de
pointes. (Cardiol J 2009; 16, 2: 172–174)
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Introduction
Fluoroquinolones are frequently used antibac-
terial agents with a wide efficacy spectrum [1].
However, prolongation of the QT interval related
to the effect of these drugs on rapid potassium chan-
nels (IKr) may result on potentially serious proarr-
hythmic effect, leading to torsades de pointes [2].
Several quinolones, including sparfloxacin and gre-
pafloxacin have been withdrawn from the market
by the manufacturer, when associated with QT-re-
lated arrhythmias [3]. Current clinical studies sug-
gest that among quinolones, ciprofloxacin has no
effect on QT interval in healthy subjects with no
predisposing factors [4, 5] and weak effect in pa-
tients with pre-existing risk factors for torsades de
pointes [6, 7]. Ciprofloxacin is given to selected
patients because is considered to be safer than other
agents in its class.
The upper limit for duration of the normal QT
interval corrected for heart rate (QTc) is often gi-
ven as 0.44 s. However, the normal QTc may actu-
ally be longer (0.46 for men and 0.47 for women)
with a normal range of plus or minus 15% of the
mean value [8]. Prolonged QT interval may be as-
sociated with a polymorphic ventricular tachycar-
dia known as torsades de pointes. Congenital long
QT syndromes, female gender, hypokalemia and
use of sympathomimetics drugs increase the risk
of torsades. Antiarrhythmics that block the potassium
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channel prolong the QT and increase the risk for
torsades (amiodarone, sotalol, quinidine, disopyra-
mide, procainamide, ibutilide). Additionally, some
macrolide and fluoroquinolone antibiotics, antipsy-
chotic and antidepressant drugs, serotonin agoni-
sts of the triptan class, cisapride, dolasetron and
others, have been reported to be associated with
QT prolongation or cases of torsades [9].
Quinolones are common antibiotic agents with
wide antimicrobial efficacy spectrum having effect
on IKr. Ciprofloxacin is often used in high risk patients
for QT mediated arrhythmia because of its lower rate
of QT prolongation and torsades de pointes.
Case presentation
A 70-year-old woman with no previous cardiac
history was admitted to the hospital for new onset
atrial fibrillation with rapid ventricular response.
On admission she was on amiodarone 450 mg i.v.
in 30 minutes loading dose and 650 mg in
24-hour infusion rate and digoxin 0.25 mg/day. The
patient converted to sinus rhythm within 48 hours
of admission. Digoxin and amiodarone was discon-
tinued and sotalol 40 mg p.o. bid was administered.
Next day the patient presented with with jaundice,
fever, and right abdominal pain diagnosed by ultra-
sound as cholecystitis. Laboratory test results re-
vealed high WBC level (20,730), high total and di-
rect bilirubin (3.82 mg/dL and 1.98 mg/dL, respec-
tively) and low potassium levels (3.00 mmol/L).
Ciprofloxacin 400 mg i.v. bid was administered.
Within 12 hours, she had syncope with a documented
torsades de pointes requiring defibrillation (Fig. 1A).
Prior to initiation of ciprofloxacin QTc was 0.38
(Fig. 1B). After resuscitation, QTc was markedly
increased at 0.62 (Fig. 1C). Intravenous magnesium
was administered. Sotalol and ciprofloxacin was di-
scontinued. QT normalized to 0.42 within 3 days of
drug cessation (Fig. 1D).
Figure 1. ECG from the patient shows sinus rhythm on sotalol 40 mg bid (baseline, QTc = 0.38) (A), during torsades
de pointes (rhythm strip) (B), immediately after resuscitation (QTc = 0.62) (C) and 72 hours after discontinuation of
ciprofloxacin and antiarrhythmic therapy (QTc = 0.42) (D).
C
D
B
A
174
Cardiology Journal 2009, Vol. 16, No. 2
www.cardiologyjournal.org
Conclusions
Fluoroquinolones are common antibacterial
agents that directly inhibit the synthesis of DNA by
inactivation of two enzymes [1]. They are common-
ly used because of their wide antimicrobial efficacy
in common respiratory, gastrointestinal and geni-
tourinary infections. Among fluoroquinolones, mo-
xifloxacin appears to have the greatest risk of
QT prolongation and it should be used with caution
in patients with predisposing factors. Gemifloxacin,
levofloxacin and ofloxacin are related with lower
risk of prolongation of QT. However, they should
be used with caution in high risk patients [10–12].
Ciprofloxacin has been associated with the lowest
risk for QT prolongation and torsades de pointes [2].
The case presented here demonstrates ciprofloxa-
cin’s involvement in generation of QT mediated pro-
arrhythmia. It is of notice, that many predisposing
and risk factors were present in this case. Neverthe-
less, initiation of ciprofloxacin had a clear temporal ef-
fect in QT prolongation and QT mediated arrhythmia.
Frothingham compared the rates of torsades de
pointes associated with ciprofloxacin, ofloxacin, le-
vofloxacin, gatifloxacin and moxifloxacin administra-
ton in a retrospective study between 1/1/1996 and
2/5/2001. Ciprofloxacin was associated with a signi-
ficantly lower rate of torsades de pointes (0.3 ca-
ses/10 million prescriptions, 95% confidence inte-
rval (CI) 0.0–1.10 than levofloxacin 95.4/10 million,
95% CI 2.9–9.3, p < 0.001) or gatifloxacin (27/
/10 million, 95% CI 12–53, p < 0.0.001 for compa-
rison with ciprofloxacin or levofloxacin) [6]. Thus,
ciprofloxacin is commonly administered due to its
low potential to cause QT mediated arrhythmias.
In an open label crossover study, 13 healthy
participants received 3 standard treatment courses
with ciprofloxacin, levofloxacin and moxifloxacin.
No difference was seen in baseline QTc (0.48) or
QTd (0.92). Following 7 days of moxifloxacin, the
QTc was prolonged by 6ms relative to baseline
(408 ms, p = 0.0022) and 11 ms from 2 hour me-
asurement (403 ms, p = 0.003). Ciprofloxacin and
levofloxacin had no effect on QTc and no fluoroqu-
inolone changed the QTd [5].
In another study, changes in QT and QTc inte-
rval from baseline values were assessed before and
after a single high dose of levofloxacin, moxifloxa-
xin and ciprofloxacin [4]. Increases in QT and QTc
interval compared with placebo were consistently
greater after moxifloxacin compared with either
levofloxacin or ciprofloxacin. The mean post dose
change from baseline QTc intervals for the 24 hours
period after treatment with moxifloxacin ranged
from 16.34 to 17.83 ms (p < 0.001). For levofloxa-
cin, this change ranged from 3.53 to 4.88 ms (p <
< 0.05) and for ciprofloxacin this change ranged
from 2.27 to 4.93 ms (p < 0.05). Greater changes
in QT and QTc intervals after treatment with mo-
xifloxacin compared with levofloxacin or ciproflo-
xacin are consistent with in vitro observations re-
lated to the effect of these drugs on rapid potassium
channels (IKr).
Although rare, ciprofloxacin must be used with
caution because its potential to cause QT prolon-
gation and life threatening arrhythmias, especially
in patients with other risk factors.
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